The Southern Research Molecular Libraries Screening Center (SRMLSC) is based at Southern Research Institute, where more than 20 anti-cancer drugs have been discovered and entered into clinical trials; six of those drugs were marketed upon receiving FDA approval. The SRMLSC brings extensive drug discovery and development expertise to the network, especially in the areas of cancer, neurological diseases/CNS disorders, and infectious disease (HIV, hepatitis, TB, and emerging pathogens including influenza, H5N1 Avian flu, West Nile virus and SARS coronavirus). Learn more about SRMLSC.

Biological Expertise

  • Cancer
  • Infectious diseases
  • Neurodegenerative diseases

Screening Capabilities

  • BSL-3 Assays
  • Cell Based Assays

    •    - Mammalian
       - Bacteria
       - Yeast
  • Target Based Assays
       - Enzyme
       - Reporter
       - Protein-protein interaction

Resources

PubChem is a public database with annotated information about the biological activities of compounds in the Molecular Libraries Small Molecule Repository (MLSMR) as well as compound probe information provided from Molecular Libraries Roadmap research and other sources.

 

The Molecular Libraries Roadmap offers public sector biomedical researchers access to the large-scale screening capacity necessary to identify small molecules that can be optimized as chemical probes to study the functions of genes, cells, and biochemical pathways.